Physician profile
Michael S Halata
NPI 1922008739
$1,931.06
in general payments reported to CMS, 2019-2025
12 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $141 · 2021: $62.18 · 2022: $254 · 2023: $550 · 2024: $296 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $493.55 | 2022-2025 | |
| Cumberland Pharmaceuticals, INC. | $472.21 | 2019-2025 | Kristalose |
| Janssen Biotech, INC. | $205.70 | 2019-2023 | Stelara |
| Abbvie INC. | $189.38 | 2019 | |
| Qol Medical, LLC | $163.87 | 2023-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $139.30 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $119.81 | 2022-2025 | Gattex, Eohilia |
| Nestle Healthcare Nutrition INC. | $51.39 | 2022-2023 | |
| Celltrion USA INC. | $25.11 | 2024 | Vegzelma |
| Biocon Biologics INC | $24.61 | 2024 | Hulio |
| Ironwood Pharmaceuticals, INC | $23.95 | 2024 | |
| Travere Therapeutics, INC. | $22.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Halata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.